Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Rattus norvegicus | Glutamate [NMDA] receptor subunit epsilon 2 | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Echinococcus granulosus | glutamate NMDA receptor subunit | Get druggable targets OG5_129290 | All targets in OG5_129290 |
Schistosoma mansoni | glutamate receptor NMDA | Get druggable targets OG5_129290 | All targets in OG5_129290 |
Echinococcus multilocularis | glutamate (NMDA) receptor subunit | Get druggable targets OG5_129290 | All targets in OG5_129290 |
Schistosoma japonicum | ko:K05314 glutamate receptor, ionotropic, N-methyl-D-aspartate 2, invertebrate, putative | Get druggable targets OG5_129290 | All targets in OG5_129290 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium ulcerans | proteasome PrcB | 0.0077 | 1 | 0.5 |
Trypanosoma cruzi | proteasome subunit beta type-5, putative | 0.0077 | 1 | 1 |
Echinococcus multilocularis | glutamate (NMDA) receptor subunit | 0.0076 | 0.9794 | 0.9794 |
Mycobacterium tuberculosis | Proteasome beta subunit PrcB; assembles with alpha subunit PrcA. | 0.0077 | 1 | 0.5 |
Schistosoma mansoni | proteasome catalytic subunit 3 (T01 family) | 0.0077 | 1 | 1 |
Echinococcus multilocularis | proteasome (prosome, macropain) subunit, beta | 0.0034 | 0.0474 | 0.0474 |
Plasmodium falciparum | proteasome subunit beta type-5 | 0.0077 | 1 | 1 |
Trypanosoma cruzi | proteasome subunit beta type-5, putative | 0.0077 | 1 | 1 |
Echinococcus granulosus | glutamate NMDA receptor subunit | 0.0076 | 0.9794 | 0.9794 |
Schistosoma mansoni | glutamate receptor NMDA | 0.0076 | 0.9794 | 0.9784 |
Echinococcus multilocularis | proteasome (prosome, macropain) | 0.0077 | 1 | 1 |
Echinococcus granulosus | proteasome prosome macropain | 0.0077 | 1 | 1 |
Giardia lamblia | Proteasome subunit beta type 5 precursor | 0.0077 | 1 | 1 |
Echinococcus granulosus | proteasome prosome macropain subunit beta | 0.0034 | 0.0474 | 0.0474 |
Trypanosoma brucei | proteasome subunit beta type-5, putative | 0.0077 | 1 | 1 |
Entamoeba histolytica | proteasome subunit beta type 5 precursor, putative | 0.0077 | 1 | 1 |
Loa Loa (eye worm) | proteasome A-type and B-type family protein | 0.0077 | 1 | 1 |
Plasmodium vivax | proteasome subunit beta type-5, putative | 0.0077 | 1 | 1 |
Mycobacterium leprae | proteasome (beta subunit) PrcB | 0.0077 | 1 | 0.5 |
Toxoplasma gondii | proteasome subunit beta type, putative | 0.0077 | 1 | 1 |
Trichomonas vaginalis | Family T1, proteasome beta subunit, threonine peptidase | 0.0077 | 1 | 1 |
Leishmania major | proteasome beta 5 subunit, putative | 0.0077 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
F (ADMET) | = 27 % | Bioavailability in mouse | ChEMBL. | 17768047 |
F (ADMET) | = 27 % | Bioavailability in mouse | ChEMBL. | 17768047 |
IC50 (binding) | = 10 nM | Displacement of [3H]CP101,606 from NR2B in rat forebrain P2 membrane | ChEMBL. | 17768047 |
IC50 (binding) | = 10 nM | Displacement of [3H]CP101,606 from NR2B in rat forebrain P2 membrane | ChEMBL. | 17768047 |
IC50 (binding) | > 30 uM | Displacement of [3H]dofetilide from human HERG expressed in HEK293 cells | ChEMBL. | 17768047 |
IC50 (binding) | > 30 uM | Displacement of [3H]dofetilide from human HERG expressed in HEK293 cells | ChEMBL. | 17768047 |
Inhibition (binding) | = 9 % | Inhibition of HERG current at 30 uM | ChEMBL. | 17768047 |
Inhibition (binding) | = 9 % | Inhibition of HERG current at 30 uM | ChEMBL. | 17768047 |
MED (functional) | = 10 mg Kg-1 | Antiallodynic activity in po dosed mouse partial sciatic nerve ligation model | ChEMBL. | 17768047 |
MED (functional) | = 10 mg Kg-1 | Antiallodynic activity in po dosed mouse partial sciatic nerve ligation model | ChEMBL. | 17768047 |
Solubility | = 130 ug ml-1 | Solubility at pH 6.5 | ChEMBL. | 17768047 |
t1/2 (ADMET) | > 60 min | Metabolic stability assessed Half life in human liver microsomes | ChEMBL. | 17768047 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.